Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 3
Submit an article Journal homepage
202
Views
1
CrossRef citations to date
0
Altmetric
Commentaries

Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cure

Christopher MelaniLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USACorrespondence[email protected]
&
Wyndham H. WilsonLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Pages 511-513 | Received 25 Oct 2021, Accepted 31 Oct 2021, Published online: 11 Nov 2021

References

  • Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511.
  • Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378(15):1396–1407.
  • Bartlett NL, Wilson WH, Jung SH, et al. Dose-Adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-Cell lymphoma: Clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–1799.
  • Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408–1416.
  • Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609–e617.
  • Puckrin R, Ghosh S, Peters A, et al. Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities. Leukemia & Lymphoma. 2021;1–8. doi:10.1080/10428194.2021.1992762.
  • Danesi R, Fogli S, Gennari A, et al. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet. 2002;41(6):431–444.
  • Menna P, Salvatorelli E. Primary prevention strategies for anthracycline cardiotoxicity: a brief overview. Chemotherapy. 2017;62(3):159–168.
  • Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000;18(21):3633–3642.
  • Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017–3024.
  • Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with burkitt's lymphoma. N Engl J Med. 2013;369(20):1915–1925.
  • Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of Risk-Adapted therapy with Dose-Adjusted EPOCH-R in adults with untreated burkitt lymphoma. J Clin Oncol. 2020;38(22):2519–2529.
  • Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet (London, England). 2019;394(10216):2271–2281.
  • Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. The Lancet Oncology. 2015;16(5):541–549.
  • Younes A, Sehn LH, Johnson P, PHOENIX investigators, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in Non-Germinal center B-Cell diffuse large B-Cell lymphoma. J Clin Oncol. 2019;37(15):1285–1295.
  • Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-Type diffuse large B-Cell lymphoma. J Clin Oncol. 2021;39(12):1317–1328.
  • Nowakowski GS, Hong F, Scott DW, et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-Cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412. J Clin Oncol. 2021;39(12):1329–1338.
  • Westin JR, Nastoupil LJ, Fayad L, et al. Smart start: Rituximab, lenalidomide, and ibrutinib alone and in combination with standard chemotherapy for patients with newly diagnosed diffuse large B-Cell lymphoma: Final phase II results. Blood. 2019;134(Supplement_1):1581–1581.
  • Melani C, Lakhotia R, Pittaluga S, et al. Phase 1b/2 study of vipor (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in relapsed/refractory B-Cell lymphoma: Safety, efficacy and molecular analysis. Blood. 2020;136(Supplement 1):44–45.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.